The present invention, depression, anxiety disorder, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders (eg, schizophrenia), neurological diseases (eg, Parkinson's disease), neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, drug abuse, and metabolic disorders (for example, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation), body temperature homeostasis disorders and abnormal, for the manufacture of a medicament for the treatment of sleep and circadian rhythm disorders and cardiovascular disorders, in the formula I [wherein, R is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, or lower alkyl substituted by halogen, or _{4- (CH 2) 2 C (} O) - naphthyl; X is -S- or -NH-; aryl is phenyl, naphthalen-1-yl, an aromatic group selected from naphthalene-2-yl or 5,6,7,8-tetrahydronaphthalen-1-yl; hetaryl, containing at least one N or S ring atom and, an aromatic group selected from the group consisting of thiophen-3-yl or pyrimidin-5-yl; n is, the compounds of 1, 2 or 3], and salts thereof pharmaceutically active, racemic mixture, enantiomers, it relates to the use of a form of optical isomers and tautomers.